

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Henlius Biotech, Inc.**

**上海復宏漢霖生物技術股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2696)**

## **INSIDE INFORMATION**

### **TERMINATION OF LISTING TUTORING**

This announcement is made by Shanghai Henlius Biotech, Inc. (the “**Company**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the circular of the Company dated 8 April 2022 (the “**Circular**”) in relation to, among other things, the extension of the resolutions in relation to the proposed initial public offering of A Shares and the listing of A Shares on the Science and Technology Innovation Board of Shanghai Stock Exchange and the extension of the validity period of the authorization to the board of directors to deal with relevant matters. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The board of directors of the Company (the “**Board**”) hereby announces that, taking into account the Company’s actual situation and the plan of the Company in the capital market, the Board has decided not to proceed further with the A Share Offering and listing on the SSE STAR Market, and the Company and the listing tutoring institution also unanimously agreed to terminate the listing tutoring agreement in relation to the A Share Offering and Listing. With the deepening of the Group’s commercialization process, the Board is of the view that the above matters will not have a material adverse impact on the Group’s daily operations.

**The Company will consider its own development needs and market conditions and make plans for relevant arrangements on the capital market in due course. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

On behalf of the Board  
**Shanghai Henlius Biotech, Inc.**  
**Wenjie Zhang**  
*Chairman*

Hong Kong, 3 July 2023

*As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Mr. Zihou Yan as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive Directors.*